Comparative Pharmacology
Head-to-head clinical analysis: ANTIZOL versus METHYLENE BLUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIZOL versus METHYLENE BLUE.
ANTIZOL vs METHYLENE BLUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the oxidation of ethanol to acetaldehyde. It also inhibits the metabolism of ethylene glycol and methanol to their toxic metabolites.
Methylene blue is a dye that acts as a redox agent, reducing methemoglobin to hemoglobin by activating the enzyme methemoglobin reductase. It also inhibits nitric oxide synthase and guanylate cyclase, causing vasoconstriction in septic shock.
Initial: 15 mg/kg IV over 10 minutes, then 3 mg/kg IV every 4 hours for 2 doses, then 3 mg/kg IV every 6 hours for 4 doses.
1-2 mg/kg IV over 5-30 minutes for methemoglobinemia; repeat after 1 hour if needed. Maximum dose: 7 mg/kg.
None Documented
None Documented
Clinical Note
moderateMethylene blue + Torasemide
"Methylene blue may increase the hypotensive activities of Torasemide."
Clinical Note
moderateMethylene blue + Travoprost
"Methylene blue may increase the hypotensive activities of Travoprost."
Clinical Note
moderateMethylene blue + Unoprostone
"Methylene blue may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateMethylene blue + Hydrochlorothiazide
Terminal elimination half-life: 2.5-3.5 hours in adults. Clinical context: Dose adjustment recommended in severe renal impairment (CrCl <30 mL/min) due to prolonged half-life.
Terminal elimination half-life approximately 12–24 hours; clinically, levels may persist for 2–3 days due to enterohepatic recycling
Renal: 80-95% as parent drug and metabolites. Fecal: <5%. Biliary excretion is negligible.
Renal (80% as leukomethylene blue and unchanged drug); biliary/fecal minor
Category C
Category C
Antidote
Antidote
"Methylene blue may increase the hypotensive activities of Hydrochlorothiazide."